ArticleHaematologica2024

TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma.

Larissa Valle Guilhen Longo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.